Study summary

A gene-targeting drug cut convulsive seizures in children with Dravet syndrome

MONARCH and ADMIRAL studies (zorevunersen) · 81 children and teens, phase 1/2a · Published March 2026, New England Journal of Medicine

58.82%or greater median drop in convulsive seizures at the highest dose (open-label)

What was tested

Zorevunersen, an antisense drug given into the spinal fluid to raise levels of the NaV1.1 sodium channel that is missing in Dravet syndrome. Open-label, no comparison group.

What they found

What it means

The first treatment aimed at the cause of Dravet syndrome; a phase 3 trial is under way.

N Engl J Med, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.